120 related articles for article (PubMed ID: 36607144)
1. SETD2 detection may reveal response to induction therapy and survival profile in acute myeloid leukemia patients.
Liu H
Hematology; 2023 Dec; 28(1):2161194. PubMed ID: 36607144
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
Wang S; Yuan X; Liu Y; Zhu K; Chen P; Yan H; Zhang D; Li X; Zeng H; Zhao X; Chen X; Zhou G; Cao S
J Transl Med; 2019 Mar; 17(1):101. PubMed ID: 30922329
[TBL] [Abstract][Full Text] [Related]
3. Circular RNA SPI1 expression before and after induction therapy and its correlation with clinical features, treatment response, and survival of acute myeloid leukemia patients.
Xiong T; Xia L; Song Q
J Clin Lab Anal; 2023 Feb; 37(3):e24835. PubMed ID: 36644997
[TBL] [Abstract][Full Text] [Related]
4. Blood MALT1 deficiency is common and relates to unfavorable induction therapy response and survival profile in acute myeloid leukemia patients.
Geng H; Wang Y; Wang S
Hematology; 2022 Dec; 27(1):1176-1183. PubMed ID: 36314929
[TBL] [Abstract][Full Text] [Related]
5. SUMO specific peptidase 1 decreases after induction treatment, and its reduction predicts lower disease risk, better treatment response, longer survival of acute myeloid leukemia.
Liu J; Li Y; Zhang G
Scand J Clin Lab Invest; 2023 Sep; 83(5):283-289. PubMed ID: 37405376
[TBL] [Abstract][Full Text] [Related]
6. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
7. Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study.
Wang L; Zhao N; Zhou L; Tong J; Xue L; Zhang L; Han Y; Wang X; Geng L; Tang B; Liu H; Zhu W; Cai X; Liu X; Zhu X; Sun Z; Zheng C
Clin Interv Aging; 2022; 17():55-64. PubMed ID: 35082491
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
Luo W; Yu H; Zou X; Ni X; Wei J
Cancer Biomark; 2018; 23(4):485-494. PubMed ID: 30347595
[TBL] [Abstract][Full Text] [Related]
9. [A long-term follow-up study of 82 children with acute myeloid leukemia].
Ruan M; Qi BQ; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):730-734. PubMed ID: 30293275
[No Abstract] [Full Text] [Related]
10. The role of circular RNA plasmacytoma variant translocation 1 as a biomarker for prognostication of acute myeloid leukemia.
Chen T; Chen F
Hematology; 2021 Dec; 26(1):1018-1024. PubMed ID: 34871521
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive].
Duan WB; Gong LZ; Jia JS; Zhu HH; Zhao XS; Jiang Q; Zhao T; Wang J; Qin YZ; Huang XJ; Jiang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):990-995. PubMed ID: 29263470
[TBL] [Abstract][Full Text] [Related]
12. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
13. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
14. [The Impact of Induction Treatment Response on the Prognosis of Pediatric Core Binding Factor-Acute Myeloid Leukemia Patients].
Zeng HM; Hu GH; Lu AD; Jia YP; Zuo YX; Wu J; Zhang LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):56-61. PubMed ID: 33554797
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.
Short NJ; Benton CB; Chen HC; Qiu P; Gu L; Pierce S; Brandt M; Maiti A; Min TL; Naqvi K; Quintas-Cardama A; Konopleva M; Kadia T; Cortes J; Garcia-Manero G; Ravandi F; Jabbour E; Kantarjian H; Andreeff M
Am J Hematol; 2016 Dec; 91(12):1221-1226. PubMed ID: 27474808
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of integrin α7 for acute myeloid leukemia risk and its correlation with prognosis in acute myeloid leukemia patients.
Zeng M; Ding S; Zhang H; Huang Q; Ren Y; Guo P
J Clin Lab Anal; 2020 Apr; 34(4):e23151. PubMed ID: 31855276
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
[No Abstract] [Full Text] [Related]
18. Potentiality of Protein phosphatase Mg
Yu M; Hu J; He D; Chen Q; Liu S; Zhu X; Li B
J Clin Lab Anal; 2020 May; 34(5):e23171. PubMed ID: 31901183
[TBL] [Abstract][Full Text] [Related]
19. [Clinical Analysis of Pediatric Acute Myeloid Leukemia with CCLG-AML 2015 Regimen].
Wang P; Xiong H; Li JX; Wang Z; Yang L; Tao F; Chen Z; DU Y; Zhang AP; Luo LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):373-380. PubMed ID: 35395966
[TBL] [Abstract][Full Text] [Related]
20. Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia.
Ciftciler R; Demiroglu H; Haznedaroglu IC; Sayınalp N; Aksu S; Ozcebe O; Goker H; Aydın MS; Buyukasık Y
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):729-734. PubMed ID: 31540855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
